Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?

Br J Dermatol. 2023 Sep 15;189(4):467-468. doi: 10.1093/bjd/ljad224.

Authors

Carlo Alberto Maronese^{1

2}, John R Ingram³, Angelo V Marzano^{1

2}

Affiliations

¹ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
² Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
³ Division of Infection and Immunity, Cardiff University, Cardiff, UK.

PMID: 37406224
DOI: 10.1093/bjd/ljad224

No abstract available

MeSH terms

Adalimumab
Biological Products*
Drug Combinations
Hidradenitis Suppurativa* / drug therapy
Humans
Infliximab

Substances

Adalimumab
Infliximab
Drug Combinations
Biological Products